Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection. Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates, meaning that infection may lead to shock, bleeding and multi-organ failure. According to the World Health Organization, Ebola hemorrhagic fever has a fatality rate of up to 90 percent. There is no licensed treatment or vaccine for Ebola virus infection.
Several research groups have developed experimental vaccine approaches that protect nonhuman primates from Ebola virus and the closely related Marburg virus. These approaches include vaccines based on DNA, recombinant adenovirus, virus-like particles, and human parainfluenza virus 3. But how these vaccine candidates confer protection is an area that is still being explored: Do they activate immune cells to kill the invading virus? Or do they elicit antibodies that block infection?
In this study, scientists at NIH's National Institute of Allergy and Infectious Diseases and OHSU's Vaccine & Gene Therapy Institute built on earlier work with an experimental vaccine composed of an attenuated vesicular stomatitis virus carrying a gene that codes for an Ebola virus protein. They observed how cynomolgus macaques responded to a challenge of Ebola virus before and during treatment with the vaccine and in conjunction with depleted levels of immune cells. Their results showed that important immune cells—CD4+ T cells and CD8+ T cells—had a minimal role in providing protection, while antibodies induced by the vaccine appeared to be critical to protecting the animals.
The scientists say this finding will help improve future Ebola virus vaccine development. They plan to focus their studies on what level of antibody production is needed to establish protection from Ebola virus infection in humans
WHO: Heinz Feldmann, M.D., Ph.D., chief of the Laboratory of Virology at NIAID's Rocky Mountain Laboratories. Dr. Feldmann is an expert on viral hemorrhagic fevers and emerging viruses.
ARTICLE: A Marzi et al. Antibodies are necessary for rVSV/ZEBOV-GP mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.1209591110 (2013).
NIH/National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
A survey of birds has identified 361 new species that had previously been confused with known species, a quarter of which are considered threatened
Wild monkeys living in forests near Japan's devastated Fukushima nuclear reactor show worrying signs of radiation exposure
Audubon Minnesota warns that a signature feature of the new Vikings stadium, a 200,000-square-foot wall of glass, could lead to thousands of bird collisions. Kim Johnson of WCCO reports.
Changes in the Antarctic climate are showing up in the fur seal population, say scientists who have studied the animals for 30 years on the British Overseas Territory of South Georgia.
The best way to protect forests, and the carbon they contain that could otherwise cause global warming, is to hand them over to local communities
Scientists disagree about some surprising data on the state of the ice in Antarctica
Augmented and virtual reality games may help crack the code of getting humans to do something about the environment
Drones detect far more ocean garbage than previously known, including debris from Japan's 2011 tsunami
Scientist estimates that eating a pound of beef causes more greenhouse warming than burning a gallon of gasoline
May was the hottest on record, too